Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
urogenital diseases | D000091642 |
endocrine system diseases | D004700 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
LYNPARZA | AstraZeneca | N-208558 RX | 2017-08-17 | 2 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
lynparza | New Drug Application | 2023-11-06 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
ovarian neoplasms | EFO_0003893 | D010051 | C56 |
Expiration | Code | ||
---|---|---|---|
OLAPARIB, LYNPARZA, ASTRAZENECA | |||
2027-05-08 | ODE-306 | ||
2026-12-27 | ODE-283 | ||
2025-12-19 | ODE-226 | ||
2025-03-11 | I-885 | ||
2024-08-17 | ODE-180, ODE-181 | ||
2023-05-19 | I-832 | ||
2023-05-08 | I-831 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Olaparib, Lynparza, Astrazeneca | |||
8859562 | 2031-08-04 | U-1634, U-2101, U-2103, U-2480, U-2482, U-2483, U-2716, U-2819, U-2820, U-2821, U-2822, U-2823, U-2824, U-2832, U-2833, U-3333, U-3631 | |
8475842 | 2029-12-31 | DP | |
11633396 | 2029-10-07 | DP | |
8247416 | 2028-09-24 | DP | |
8071579 | 2027-08-12 | U-2101, U-2103, U-2480, U-2482, U-2483, U-2716, U-2819, U-2820, U-2821, U-2822, U-2823, U-2824, U-2832, U-2833, U-3333, U-3631 | |
8143241 | 2027-08-12 | U-1634, U-2101, U-2103, U-2480, U-2482, U-2483, U-2716, U-2819, U-2820, U-2821, U-2822, U-2823, U-2824, U-2832, U-2833, U-3333, U-3631 | |
7449464 | 2024-10-11 | DS, DP | |
7981889 | 2024-10-11 | DS, DP | |
8912187 | 2024-03-12 | U-1634, U-2101, U-2480, U-2482, U-2483, U-2819, U-2820, U-2821, U-2822, U-2823, U-2824, U-3333 | |
9169235 | 2024-03-12 | U-2832, U-2833, U-3631 | |
9566276 | 2024-03-12 | U-2716 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 10 | 23 | 11 | 2 | 12 | 54 |
Ovarian epithelial carcinoma | D000077216 | — | — | 2 | 18 | 9 | 3 | 9 | 40 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 12 | 20 | 6 | 1 | 3 | 38 |
Prostatic neoplasms | D011471 | — | C61 | 2 | 15 | 3 | 1 | 5 | 26 |
Castration-resistant prostatic neoplasms | D064129 | — | — | — | 7 | 3 | 1 | 2 | 13 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Carcinoma | D002277 | — | C80.0 | 6 | 9 | 1 | — | 1 | 17 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 7 | 1 | — | 2 | 12 |
Endometrial neoplasms | D016889 | EFO_0004230 | — | 2 | 5 | 4 | — | 2 | 11 |
Adenocarcinoma | D000230 | — | — | 1 | 7 | 2 | — | — | 10 |
Recurrence | D012008 | — | — | 2 | 4 | 2 | — | 1 | 9 |
Hereditary breast and ovarian cancer syndrome | D061325 | — | — | 1 | 4 | 2 | — | 1 | 7 |
Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | 4 | 1 | — | — | 5 |
Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | 1 | 3 | — | 1 | 5 |
Colorectal neoplasms | D015179 | — | — | 1 | 2 | 1 | — | — | 4 |
Fallopian tube neoplasms | D005185 | — | — | 2 | 1 | 1 | — | — | 4 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 23 | 9 | — | — | — | 31 |
Triple negative breast neoplasms | D064726 | — | — | 4 | 7 | — | — | — | 11 |
Lung neoplasms | D008175 | — | C34.90 | 3 | 7 | — | — | — | 9 |
Small cell lung carcinoma | D055752 | — | — | 3 | 5 | — | — | — | 7 |
Non-small-cell lung carcinoma | D002289 | — | — | 1 | 5 | — | — | — | 6 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | 3 | 2 | — | — | — | 4 |
Squamous cell carcinoma | D002294 | — | — | 3 | 1 | — | — | — | 4 |
Sarcoma | D012509 | — | — | 1 | 3 | — | — | — | 4 |
Renal cell carcinoma | D002292 | EFO_0000376 | — | — | 3 | — | — | — | 3 |
Urinary bladder neoplasms | D001749 | — | C67 | 1 | 2 | — | — | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Head and neck neoplasms | D006258 | — | — | 2 | — | — | — | — | 2 |
Squamous cell neoplasms | D018307 | — | — | 2 | — | — | — | — | 2 |
Laryngeal neoplasms | D007822 | EFO_0003817 | C32 | 1 | — | — | — | — | 1 |
Hyperthermia | D000084462 | — | — | 1 | — | — | — | — | 1 |
Lymphoma | D008223 | — | C85.9 | 1 | — | — | — | — | 1 |
Thyroid neoplasms | D013964 | EFO_0003841 | — | 1 | — | — | — | — | 1 |
Male genital neoplasms | D005834 | — | — | 1 | — | — | — | — | 1 |
Bone neoplasms | D001859 | EFO_0003820 | D16 | 1 | — | — | — | — | 1 |
Brca1 genes | D019398 | — | — | 1 | — | — | — | — | 1 |
Telomeric repeat binding protein 2 | D035341 | — | — | 1 | — | — | — | — | 1 |
Drug common name | Olaparib |
INN | olaparib |
Description | Olaparib is a member of the class of N-acylpiperazines obtained by formal condensation of the carboxy group of 2-fluoro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]benzoic acid with the free amino group of N-(cyclpropylcarbonyl)piperazine; used to treat advanced ovarian cancer. It has a role as an antineoplastic agent, an EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor and an apoptosis inducer. It is a N-acylpiperazine, a member of cyclopropanes, a member of monofluorobenzenes and a member of phthalazines. |
Classification | Small molecule |
Drug class | poly-ADP-ribose polymerase inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1 |
PDB | — |
CAS-ID | 763113-22-0 |
RxCUI | — |
ChEMBL ID | CHEMBL521686 |
ChEBI ID | 83766 |
PubChem CID | 23725625 |
DrugBank | DB09074 |
UNII ID | WOH1JD9AR8 (ChemIDplus, GSRS) |